Plain-English translation of NCT07044921 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new formulation of irinotecan (a chemotherapy drug) combined with two targeted medications called cetuximab and bevacizumab. The study is designed for people whose colorectal cancer has stopped responding to previous irinotecan-based treatments. Researchers want to see if this new combination can help slow or stop the cancer's growth and how well patients tolerate the treatment.
When colorectal cancer becomes resistant to standard irinotecan chemotherapy, treatment options become very limited. This medication is designed to work differently and potentially overcome that resistance, offering hope to patients who have exhausted other options.
You likely qualify if…
You likely don't qualify if…
You would receive the three-drug combination (irinotecan liposome, cetuximab, and bevacizumab) starting on day 1 of each treatment cycle. Treatment cycles last 2 weeks, and after each cycle your doctor will evaluate how well the treatment is working using imaging scans. Depending on how you're responding and tolerating the medications, your doctor will decide whether to continue, adjust, or stop treatment. You may continue even after initial signs of progression if your doctor believes you're still benefiting and tolerating the treatment well.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Chinese PLA General Hospital
Enrollment target
~30 participants
Started
September 2024
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Guanghai Dai, Doctor
Chinese PLA General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.